Category Industry Updates

TwoStep Therapeutics Raises $62.5M Series A and Secures FDA IND Clearance for First-in-Class Peptide-Drug Conjugate

TwoStep Therapeutics Secures $62.5 Million Series A and FDA Clearance for TS-104 Phase 1 Trial TwoStep Therapeutics, a biotechnology company developing multi-specific targeted therapies for solid tumors, has announced two significant milestones that mark the company’s transition into clinical development.…

Read MoreTwoStep Therapeutics Raises $62.5M Series A and Secures FDA IND Clearance for First-in-Class Peptide-Drug Conjugate

Foot Levelers Announces First Chiropractic PracticeXcelerator® Continuing Education and Headquarters Tour

Foot Levelers Announces First-Ever Founder’s Edition PracticeXcelerator Workshop for Chiropractors Foot Levelers, a global leader in custom stabilizing orthotics, has announced its first-ever Founder’s Edition event, an expanded educational and professional development program designed specifically for chiropractors. The two-day event…

Read MoreFoot Levelers Announces First Chiropractic PracticeXcelerator® Continuing Education and Headquarters Tour

RMA New Jersey Welcomes Reproductive Endocrinologist Dr. Blake Vessa to Expand Fertility Care

IVI RMA North America Welcomes Reproductive Endocrinologist Dr. Blake Vessa to RMA New Jersey IVI RMA North America, a leader in fertility care and assisted reproductive medicine, has announced the appointment of Dr. Blake Vessa, a reproductive endocrinologist and infertility…

Read MoreRMA New Jersey Welcomes Reproductive Endocrinologist Dr. Blake Vessa to Expand Fertility Care

Encoded Therapeutics Presents Updated ETX101 Data from POLARIS Trials in Dravet Syndrome

Encoded Therapeutics Reports Durable Seizure Reduction and Neurodevelopmental Gains With ETX101 in Dravet Syndrome Encoded Therapeutics, Inc., a clinical-stage biotechnology company focused on developing precision genetic medicines for severe neurological disorders, has announced new Phase 1/2 clinical data for ETX101,…

Read MoreEncoded Therapeutics Presents Updated ETX101 Data from POLARIS Trials in Dravet Syndrome

Segal Trials Launches CISCRP’s 8th Annual Medical Heroes Appreci-A-Thon

Segal Trials Employees Join CISCRP Medical Heroes Appreci-A-Thon to Honor Clinical Research Participants and Professionals More than 90 employees from Segal Trials are participating in the 8th Annual Medical Heroes Appreci-A-Thon organized by the Center for Information and Study on…

Read MoreSegal Trials Launches CISCRP’s 8th Annual Medical Heroes Appreci-A-Thon

Gabrail Cancer Center Launches Study of Elranatamab and Low-Dose Lenalidomide

Gabrail Cancer and Research Center Receives FDA Clearance to Advance STAR-LLD and Elranatamab Study in Multiple Myeloma The Gabrail Cancer and Research Center, a PhaseWell Research site, has announced an important regulatory milestone for an investigator-initiated clinical trial evaluating STAR-LLD…

Read MoreGabrail Cancer Center Launches Study of Elranatamab and Low-Dose Lenalidomide

Cencora’s Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement for Health Systems

Cencora Launches Cell and Gene Therapy Enablement Service to Help Health Systems Expand Advanced Therapy Programs Cencora has launched a new service designed to help health systems evaluate, establish, and scale cell and gene therapy (CGT) programs as the number…

Read MoreCencora’s Accelerate Pharmacy Solutions Launches Cell and Gene Therapy Enablement for Health Systems

Naturmega to Introduce SUPRIAX2™ Solution to North American Market at SupplySide Global 2026

Naturmega to Introduce SUPRIAX2™ and Showcase Next-Generation Lipid Innovation at SupplySide Global 2026 Naturmega, an advanced lipid science company focused on omega-3 and next-generation lipid technologies, is preparing to introduce SUPRIAX2™ to the North American market at SupplySide Global 2026…

Read MoreNaturmega to Introduce SUPRIAX2™ Solution to North American Market at SupplySide Global 2026

Agenus Reports Deep Pathologic Responses and No Recurrences in Updated NEST Phase 2 Colon Cancer Data

Agenus Reports Updated NEST Phase 2 Results Supporting Neoadjuvant BOT+BAL in Colon Cancer Agenus Inc. (Nasdaq: AGEN), a biotechnology company focused on immuno-oncology innovation, has announced the peer-reviewed publication of updated results from the investigator-sponsored Phase 2 NEST clinical trial…

Read MoreAgenus Reports Deep Pathologic Responses and No Recurrences in Updated NEST Phase 2 Colon Cancer Data

Axoft Launches Fleuron® WISE, Expanding Its Advanced Polymer Portfolio

Axoft Introduces Fleuron WISE Elastomer to Enable High-Resolution Imaging in Aqueous Environments Axoft, a neurotechnology company developing advanced materials and technologies for applications at the intersection of biology and electronics, has announced the introduction of Fleuron® Water Invisible Soft Elastomer…

Read MoreAxoft Launches Fleuron® WISE, Expanding Its Advanced Polymer Portfolio

GeneDx Study Supports Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s

GeneDx Study Shows Hospital-Wide Rapid Genome Sequencing Can Improve Pediatric Diagnosis, Outcomes and Health System Efficiency GeneDx (Nasdaq: WGS), a company focused on rare disease diagnosis and the use of genomic information to improve health outcomes, has announced new findings…

Read MoreGeneDx Study Supports Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children’s